EGFR and cancer: Most EGFR mutations are either short deletions in exon 19 or an L858R substitution in exon 20 [6], and these EGFR-activating mutations subsequently stimulate EGFR downstream signaling pathways, which leads to the proliferation and invasion of cancer cells [7].